Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "HIMS"


24 mentions found


The company reported an adjusted $2.11 per share on revenue of $8.31 billion, while analysts polled by Refinitiv forecasted $1.98 and $7.58 billion. Analysts surveyed by Refinitiv had penciled in a loss of 33 cents per share on $175 million of revenue. Palantir Technologies — Palantir Technologies slid 3.4% after the data analytics company reported its second-quarter results. Beyond Meat reported an adjusted loss of 83 cents per share on $102.1 million in revenue, while Refinitiv forecasted 86 cents and $108.4 million. Paramount Global — The media conglomerate's shares climbed more than 2% in premarket trading after the company reported a quarterly earnings and revenue beat.
Persons: Goldman Sachs, NASH, Banks, Moody's, Eli Lilly, EchoStar, Charlie Ergen, Refinitiv, Lucid, Palantir, Hims, Simon & Schuster, Yun Li, Samantha Subin, Sarah Min, Pia Singh, Jesse Pound Organizations: Sagimet, Goldman, T Bank, Citizens Financial, Bank of New York Mellon, Truist, JPMorgan Chase, Telsey, Refinitiv, Novo Nordisk —, Dish, United Parcel Service, behemoth, UPS, Palantir, Paramount Global, Paramount, KKR Locations: New York, Banks —
Chegg notched second-quarter revenue of $183 million, while analysts polled by Refinitiv had expected $177 million. Analysts polled by Refinitiv called for a 5 cent loss per share and revenue of $205 million. Paramount Global — The media conglomerate added almost 4% in extended trading hours after posting an earnings and revenue beat. In the second quarter, the company reported $150.9 million in revenue against analysts' estimate of $175 million, per Refinitiv. Celanese — The materials stock fell nearly 3% after missing on both the top and bottom line in the second quarter.
Persons: Chegg, Refinitiv, Celanese Organizations: Paramount Global
"We were shocked," a former employee in Truepill's business development division said of the layoffs. Insider spoke with five former and two current Truepill employees about the challenges the company is confronting after a tumultuous year. Truepill was hiring employees rapidly, accumulating about 1,800 employees by the spring of 2022, according to one former employee in Truepill's business division. Since then, there's been a companywide push to inch closer to profitability, one of the current employees told Insider. It's also downsizing its Miami pharmacy, the current employee said.
That realization led portfolio manager David Miller to launch the Catalyst Insider Buying Fund (INSIX) nearly 12 years ago. While many funds factor in insider transactions when selecting stocks, few use it as their main prerequisite when screening investments. But in the last 12 months, it's the best-performing large-cap fund on the market through April 30, according to Kiplinger. All of these companies have benefitted from insider buying to some extent, but some have been lifted even more by company buybacks. "They've just been gobbling up their own stock," Miller said of O'Reilly Automotive.
'As startups dive into prescribing hot new weight loss drugs, Hims & Hers is taking a backseat. Its CEO said Hims wants to offer GLP-1s for weight loss, but thinks it's too early. He cited challenges in the young market like insurers refusing to cover GLP-1s and drug shortages. After Hims & Hers' first profitable quarter ever, the startup is thinking about getting in on telehealth's weight-loss craze. An 'inconsistent' supply chainExploding demand for the new weight-loss drugs has also resulted in shortages, which affect all patients prescribed GLP-1s, not just those using the drugs for weight loss.
Pharmacy startups like Capsule and Truepill are crumbling in the fight against pharmacy giants. But in the past year, the pharmacy startups have begun to crumble. Plus, each chain has thousands of stores across the country, providing the convenience that the pharmacy startups seek to replicate with tech. The digital-pharmacy shakeoutAnalysts suggested that healthcare startups with pharmacy components, rather than pure-play pharmacy startups, are best positioned to succeed. Truepill CEO Sid Viswanathan TruepillBut the pharmacy startups that have attempted to offer additional services have largely shelved those efforts in recent months.
Check out the companies making the biggest moves in premarket trading:Dish Network — The satellite company's shares fell almost 5% amid its multi-day service outage and double-downgrade from Bank of America. Revenue also beat, but Target's full-year EPS guidance came in below expectations. Arconic — Shares fell 3.5% following a downgrade to sell from neutral by Goldman Sachs. Full-year revenue guidance came in lighter than expected, but its earnings guidance topped estimates. Workday — The human resources software fell 2.4% after its revenue guidance for the first quarter came in lighter than expected.
Hims & Hers Health — Shares of the telehealth stock soared by 17% after the company reported quarterly results that surpassed estimates. However, Target's full-year earnings guidance came in below expectations. Zoom's full-year revenue guidance came in lighter than expected, but topped estimates on its earnings guidance for 2023. Norwegian Cruise Line Holdings — The cruise company fell 12% after reporting a wider-than-expected loss for the fourth quarter. Analysts surveyed by Refinitiv had forecast an 85 cents per share loss on revenue of $1.5 billion.
Eric Yuan, founder and CEO of Zoom Video Communications, stands before the opening bell during the company's initial public offering at the Nasdaq MarketSite in New York on April 18, 2019. First-quarter earnings per share guidance came in above expectations, according to Refinitiv. The energy giant missed analysts' expectations for fourth-quarter earnings and revenue, according to Refinitiv. Workday — Workday's stock fell 1% even after the human resources software company beat Wall Street's fourth-quarter revenue and earnings expectations, according to Refinitv. Hims & Hers posted a smaller-than-expected loss for the fourth quarter and revenue that came in slightly above Wall Street's expectations, according to Refinitiv.
Twentyeight Health provides underserved groups with reproductive and sexual healthcare online. See the pitch deck Twentyeight Health used to bank $8.3 million in pre-Series A funding. Twentyeight Health provides reproductive and sexual healthcare primarily for underserved communities, like low-income patients and patients of color. Twentyeight Health provided Insider with the pitch deck it used to raise $8.3 million in pre-Series A funding. Here's the 15-slide pitch deck Twentyeight Health used to bank $8.3 million.
Thrive announced at the beginning of last year it closed a massive $3 billion fund. By the end of the year, one of the fund's major investors marked down its stake by 31%. Thrive Capital, the New York-based venture firm founded in 2009 by Joshua Kushner, announced at the beginning of last year it closed a massive $3 billion fund, with $500 million earmarked for early-stage startups and another $2.5 billion devoted later-stage companies. Thrive is also in talks to make another $1 billion investment in Stripe, Bloomberg recently reported. And Thrive is also in talks to invest in OpenAI through a tender offer, the Wall Street Journal reported.
The startup Wally Health provides dental cleanings and preventative care for $199 a year. Take a look at the pitch deck Wally used to raise a $3 million seed round led by Bling Capital. That experience inspired the creation of his startup, Wally Health, which has raised $3 million in a seed round led by Bling Capital. Years before Wally, Burnett had launched businesses in media and fintech back in his native Canada. After raising a pre-seed round, Burnett and his cofounders started building Wally's proof of concept about a year ago in an office in New York's Upper East Side.
Mark Cuban has invested in the online pharmacy Truepill, he confirmed to Insider. It works with Cuban's other healthcare bet Mark Cuban Cost Plus Drug Co.Mark Cuban's interest in breaking into the healthcare industry is heating up. In November, he backed the online pharmacy Truepill through its funding round, Cuban confirmed to Insider in an email. He's played an active role in his drug-pricing startup, which launched as the Mark Cuban Cost Plus Drug Co. in 2021. When asked about the delays, Cuban said Cost Plus Drugs' volume exceeded both companies' expectations.
Mark Cuban has invested in the online pharmacy Truepill, he confirmed to Insider. Truepill works with healthcare startups to send medications through the mail. It works with Cuban's other healthcare bet Mark Cuban Cost Plus Drug Co.Mark Cuban's interest in breaking into the healthcare industry is heating up. In November, he backed the online pharmacy Truepill through its funding round, Cuban confirmed to Insider in an email. He's played an active role in his drug-pricing startup, which launched as the Mark Cuban Cost Plus Drug Co. in 2021.
To help the process, here are five stocks chosen by Wall Street's top pros, according to TipRanks, a platform that ranks analysts based on their track records. Hims & HersAnother stock that Feinseth has recently reiterated as a buy is the multi-specialty telehealth company, Hims & Hers (HIMS). Feinseth is confident in HIMS's strong brand equity and customer loyalty, which he expects will continue to drive business performance. BTIG analyst Ryan Zimmerman notes that the company stands to benefit from this space as larger players have mostly overlooked the opportunity. (See OrthoPediatrics Financial Statements on TipRanks) Last week, Zimmerman reiterated his buy rating and $62 price target on KIDS stock.
With a stock price down 45% in the last year, though, it may soon find itself on the other side of the table. But it has $732 million in cash on hand, with zero debt, and analysts are projecting 16% revenue growth. This year, though, Varonis has come back to earth — its stock price has sunk over 57% in the last 12 months. However, with strong projected 2023 revenue growth of 18.6%, Zuora remains a strong target for PE firms. Its stock price has been hammered, going down about 40% this year and making it the subject of mergers-and-acquisitions chatter.
With a stock price down 45% in the last year, though, it may soon find itself on the other side of the table. But it has $732 million in cash on hand, with zero debt, and analysts are projecting 16% revenue growth. This year, though, Varonis has come back to earth — its stock price has sunk over 57% in the last 12 months. However, with strong projected 2023 revenue growth of 18.6%, Zuora remains a strong target for PE firms. Its stock price has been hammered, going down about 40% this year and making it the subject of mergers-and-acquisitions chatter.
A janitor told BBC that a member of Elon Musk's team said his job would eventually be replaced by robots. Four former Twitter cleaners told the publication they were laid off without severance on Monday. Four former Twitter janitors told the publication they were laid off without severance on Monday. Multiple workers told the publication that they are concerned about how they will be able to pay bills in the coming weeks, particularly with the holidays coming up. "Overnight we don't have anything," Adrianna Villarreal, a cleaner who had worked at Twitter since 2018, told BBC.
In the past two years, highly funded startups have tried to disrupt mental-health care. The startups said they wanted to help solve the industry's biggest problems: Mental-health care is too expensive, and there isn't enough of it to go around. Talkspace's priority is now its division that sells mental-health care to employers, which pay recurring fees for employee access. Startups tackling more serious mental-health conditions are working with health plansThere's also a rising crop of mental-health companies tackling the costliest mental-health conditions, something the direct-to-consumer firms tend to shy away from. About half of Bicycle's patients pay with their insurance, a number he's looking to increase.
"Amazon Clinic" plays to Amazon's strengths as an ecommerce behemoth. On Tuesday, Amazon announced "Amazon Clinic," a virtual care service that will treat patients' common conditions such as allergies and hair loss. The launch comes just a couple of months after the tech giant said it was shuttering Amazon Care, a telehealth service that provided care through people's employers. By contrast, Amazon Clinic could have more success doing what it knows best, especially if it can lure Prime members. Amazon Clinic.
Retail entered into a new normal in 2022 — one where shoppers returned to stores in droves. Nike, Walmart, and startups like Tradeblock are developing new ways for consumers to shop. But unlike pre-pandemic times, consumers are now looking at brick-and-mortar as an extension of retailers' online offerings, rather than a siloed part of the business. Some of the most innovative brands like Nike, Walmart, and startups like Tradeblock are developing new ways for consumers to shop in-store and online. Each is unlike the company's previous retail stores.
United Airlines will pay $305,000 to a Buddhist pilot who refused to attend AA on religious grounds. United agreed to accommodate staff from non-Christian faiths in its program in the future. A step to regaining the certification in United's HIMS occupational substance abuse treatment program involves attending AA meetings. United rejected his suggestion of using the Buddhism-based peer support group Refuge Recovery as an alternative, the commission said. To resolve the lawsuit, United will pay the pilot $305,000 in back pay and damages and reinstate him into its HIMS program while allowing him to attend a non-12-step peer recovery program.
Once a crowdfunding darling, sexual wellness startup Dame has now raised a $7 million Series A. The 8-year-old startup believes that women's sexual wellness is key to their overall health. Here's the pitch deck Dame used to raise funding from investors like Amboy Street Ventures. One startup linked the importance of sexual pleasure to overall health and well-being in order to secure $7 million in fresh funding from VCs. But sexual health startups make up a small but growing sub-sector of the $175.6 billion global digital health market, with a few that specifically focus on women's sexual pleasure.
The mental-health startup Cerebral partnered with Alto Neuroscience for a clinical trial. The mental-health startup Cerebral is teaming up with Alto Neuroscience on an upcoming home-based clinical trial for the biopharmaceutical company Alto's depression-drug candidate, according to federal records. The idea behind the partnership is that Cerebral is a mental-health company treating patients with depression, the condition for which Alto is developing treatments. Cerebral Chief Medical Officer David Mou told TechCrunch in December that the startup provided patients for the trial "within an hour." How Alto is running the trialThe trial with Cerebral does not include a control group, according to the filing.
Total: 24